Maravai LifeSciences Holdings, Inc.
MRVI
$3.51
$0.072.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.69% | -31.73% | -27.00% | -23.92% | 3.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.69% | -31.73% | -27.00% | -23.92% | 3.23% |
| Cost of Revenue | -2.22% | 2.71% | 2.06% | 6.65% | 0.29% |
| Gross Profit | -82.46% | -74.81% | -70.11% | -51.42% | 6.81% |
| SG&A Expenses | -9.44% | -4.88% | -3.23% | 19.97% | 0.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.66% | -1.16% | -0.80% | 12.38% | 0.86% |
| Operating Income | -190.60% | -143.79% | -82.97% | -44,103.28% | 11.32% |
| Income Before Tax | 73.77% | -255.43% | -135.13% | -107.09% | -737.15% |
| Income Tax Expenses | -129.58% | -76.10% | -40.22% | -100.00% | 105.69% |
| Earnings from Continuing Operations | 73.87% | -279.14% | -133.04% | 57.72% | -1,041.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -74.13% | 250.43% | 116.07% | 405.84% | 772.47% |
| Net Income | 73.67% | -304.44% | -147.93% | 75.33% | -1,402.23% |
| EBIT | -190.60% | -143.79% | -82.97% | -44,103.28% | 11.32% |
| EBITDA | -5,497.09% | -917.71% | -185.15% | -233.25% | 118.08% |
| EPS Basic | 74.25% | -280.72% | -128.70% | 77.00% | -1,299.59% |
| Normalized Basic EPS | -106.21% | 155.41% | 50.00% | -99.93% | 2,297.57% |
| EPS Diluted | 74.25% | -280.72% | -128.70% | 77.00% | -1,271.60% |
| Normalized Diluted EPS | -106.21% | 155.41% | 50.00% | -99.93% | 2,297.57% |
| Average Basic Shares Outstanding | 2.21% | 6.18% | 8.38% | 7.32% | 7.30% |
| Average Diluted Shares Outstanding | 2.21% | 6.18% | 8.38% | 7.32% | 7.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |